Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 5/6 |
Past Performance | 4/6 |
Financial Health | 5/6 |
Dividends | 4/6 |
1061 Stock Overview
Essex Bio-Technology Limited, an investment holding company, develops, manufactures, distributes, and sells biopharmaceutical products in the People’s Republic of China and internationally.
Essex Bio-Technology Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | HK$3.52 |
52 Week High | HK$6.78 |
52 Week Low | HK$3.23 |
Beta | 0.55 |
1 Month Change | -4.87% |
3 Month Change | -8.09% |
1 Year Change | -42.76% |
3 Year Change | -32.44% |
5 Year Change | -17.76% |
Change since IPO | 255.56% |
Recent News & Updates
Is Essex Bio-Technology (HKG:1061) Using Too Much Debt?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...
Essex Bio-Technology (HKG:1061) Has Announced That It Will Be Increasing Its Dividend To HK$0.055
Essex Bio-Technology Limited's ( HKG:1061 ) dividend will be increasing to HK$0.055 on 20th of May. This makes the...
Shareholder Returns
1061 | HK Biotechs | HK Market | |
---|---|---|---|
7D | -0.3% | -3.2% | -0.9% |
1Y | -42.8% | -51.0% | -19.7% |
Return vs Industry: 1061 exceeded the Hong Kong Biotechs industry which returned -51% over the past year.
Return vs Market: 1061 underperformed the Hong Kong Market which returned -19.7% over the past year.
Price Volatility
1061 volatility | |
---|---|
1061 Average Weekly Movement | 5.1% |
Biotechs Industry Average Movement | 7.8% |
Market Average Movement | 6.5% |
10% most volatile stocks in HK Market | 12.9% |
10% least volatile stocks in HK Market | 3.2% |
Stable Share Price: 1061 is not significantly more volatile than the rest of Hong Kong stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: 1061's weekly volatility (5%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1990 | 1,379 | Haizhou Fang | https://www.essexbio.com |
Essex Bio-Technology Limited, an investment holding company, develops, manufactures, distributes, and sells biopharmaceutical products in the People’s Republic of China and internationally. The company operates through Ophthalmic Products and Surgical Products segments. It researches and develops basic fibroblast growth factor products for the treatment of cellular proliferation, differentiation, and migration.
Essex Bio-Technology Fundamentals Summary
1061 fundamental statistics | |
---|---|
Market Cap | HK$1.96b |
Earnings (TTM) | HK$345.97m |
Revenue (TTM) | HK$1.64b |
5.8x
P/E Ratio1.2x
P/S RatioIs 1061 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
1061 income statement (TTM) | |
---|---|
Revenue | HK$1.64b |
Cost of Revenue | HK$241.89m |
Gross Profit | HK$1.40b |
Other Expenses | HK$1.05b |
Earnings | HK$345.97m |
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
n/a
Earnings per share (EPS) | 0.60 |
Gross Margin | 85.23% |
Net Profit Margin | 21.13% |
Debt/Equity Ratio | 32.3% |
How did 1061 perform over the long term?
See historical performance and comparisonDividends
3.1%
Current Dividend Yield16%
Payout RatioValuation
Is 1061 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Analyst Forecast
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 1061?
Other financial metrics that can be useful for relative valuation.
What is 1061's n/a Ratio? | |
---|---|
n/a Ratio | 0x |
n/a | n/a |
Market Cap | HK$1.96b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 1.1x |
Enterprise Value/EBITDA | 4.4x |
PEG Ratio | 0.3x |
Price to Earnings Ratio vs Peers
How does 1061's PE Ratio compare to its peers?
1061 PE Ratio vs Peers |
---|
Company | PE | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 52.5x | ||
775 CK Life Sciences Int'l. (Holdings) | 55.1x | n/a | HK$7.0b |
1530 3SBio | 6.5x | 6.6% | HK$12.5b |
6826 Shanghai Haohai Biological Technology | 14.3x | 20.6% | HK$14.2b |
9995 RemeGen | 133x | 80.0% | HK$32.3b |
1061 Essex Bio-Technology | 5.8x | 21.1% | HK$2.0b |
Price-To-Earnings vs Peers: 1061 is good value based on its Price-To-Earnings Ratio (5.8x) compared to the peer average (52.5x).
Price to Earnings Ratio vs Industry
How does 1061's PE Ratio compare vs other companies in the Asian Biotechs Industry?
Price-To-Earnings vs Industry: 1061 is good value based on its Price-To-Earnings Ratio (5.8x) compared to the Hong Kong Biotechs industry average (12.1x)
Price to Earnings Ratio vs Fair Ratio
What is 1061's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PE Ratio | 5.8x |
Fair PE Ratio | 11.7x |
Price-To-Earnings vs Fair Ratio: 1061 is good value based on its Price-To-Earnings Ratio (5.8x) compared to the estimated Fair Price-To-Earnings Ratio (11.7x).
Share Price vs Fair Value
What is the Fair Price of 1061 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 1061 (HK$3.52) is trading above our estimate of fair value (HK$2.27)
Significantly Below Fair Value: 1061 is trading above our estimate of fair value.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Future Growth
How is Essex Bio-Technology forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Future Growth Score
5/6Future Growth Score 5/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE
21.1%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 1061's forecast earnings growth (21.1% per year) is above the savings rate (1.6%).
Earnings vs Market: 1061's earnings (21.1% per year) are forecast to grow faster than the Hong Kong market (17.2% per year).
High Growth Earnings: 1061's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 1061's revenue (17% per year) is forecast to grow faster than the Hong Kong market (10.1% per year).
High Growth Revenue: 1061's revenue (17% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 1061's Return on Equity is forecast to be high in 3 years time (29.6%)
Discover growth companies
Past Performance
How has Essex Bio-Technology performed over the past 5 years?
Past Performance Score
4/6Past Performance Score 4/6
Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE
15.9%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 1061 has high quality earnings.
Growing Profit Margin: 1061's current net profit margins (21.1%) are lower than last year (22.4%).
Past Earnings Growth Analysis
Earnings Trend: 1061's earnings have grown by 15.9% per year over the past 5 years.
Accelerating Growth: 1061's earnings growth over the past year (58%) exceeds its 5-year average (15.9% per year).
Earnings vs Industry: 1061 earnings growth over the past year (58%) exceeded the Biotechs industry 7.5%.
Return on Equity
High ROE: 1061's Return on Equity (19.9%) is considered low.
Discover strong past performing companies
Financial Health
How is Essex Bio-Technology's financial position?
Financial Health Score
5/6Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Debt Coverage
Interest Coverage
Financial Position Analysis
Short Term Liabilities: 1061's short term assets (HK$1.5B) exceed its short term liabilities (HK$689.6M).
Long Term Liabilities: 1061's short term assets (HK$1.5B) exceed its long term liabilities (HK$439.6M).
Debt to Equity History and Analysis
Debt Level: 1061 has more cash than its total debt.
Reducing Debt: 1061's debt to equity ratio has increased from 28.7% to 32.3% over the past 5 years.
Debt Coverage: 1061's debt is well covered by operating cash flow (73.1%).
Interest Coverage: 1061 earns more interest than it pays, so coverage of interest payments is not a concern.
Balance Sheet
Discover healthy companies
Dividend
What is Essex Bio-Technology current dividend yield, its reliability and sustainability?
Dividend Score
4/6Dividend Score 4/6
Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Cash Flow Coverage
3.12%
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: 1061's dividend (3.12%) is higher than the bottom 25% of dividend payers in the Hong Kong market (2.87%).
High Dividend: 1061's dividend (3.12%) is low compared to the top 25% of dividend payers in the Hong Kong market (8.33%).
Stability and Growth of Payments
Stable Dividend: 1061's dividend payments have been volatile in the past 10 years.
Growing Dividend: 1061's dividend payments have increased over the past 10 years.
Earnings Payout to Shareholders
Earnings Coverage: With its low payout ratio (15.8%), 1061's dividend payments are well covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: With its reasonably low cash payout ratio (40.9%), 1061's dividend payments are well covered by cash flows.
Discover strong dividend paying companies
Management
How experienced are the management team and are they aligned to shareholders interests?
21.6yrs
Average management tenure
CEO
Haizhou Fang (56 yo)
no data
Tenure
HK$2,477,422
Compensation
Mr. Haizhou Fang serves as the Managing Director and Executive Director of Essex Bio-Technology Limited and served as its General Manager. Mr. Fang is qualified as a Senior Pharmaceutical Engineer (Profess...
CEO Compensation Analysis
Compensation vs Market: Insufficient data to establish whether Haizhou's total compensation is reasonable compared to companies of similar size in the Hong Kong market.
Compensation vs Earnings: Haizhou's compensation has increased by more than 20% in the past year.
Leadership Team
Experienced Management: 1061's management team is seasoned and experienced (21.6 years average tenure).
Board Members
Experienced Board: 1061's board of directors are seasoned and experienced ( 17.9 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Essex Bio-Technology Limited's employee growth, exchange listings and data sources
Key Information
- Name: Essex Bio-Technology Limited
- Ticker: 1061
- Exchange: SEHK
- Founded: 1990
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: HK$1.959b
- Shares outstanding: 572.95m
- Website: https://www.essexbio.com
Number of Employees
Location
- Essex Bio-Technology Limited
- No. 88 Keji 6th Road
- Hi-Tech Zone
- Zhuhai
- Guangdong Province
- China
Listings
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2022/08/19 00:00 |
End of Day Share Price | 2022/08/19 00:00 |
Earnings | 2021/12/31 |
Annual Earnings | 2021/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.